小児がんバイオマーカー市場規模、シェア、動向分析レポート：適応症別、バイオマーカー別、最終用途別、セグメント予測、2024年～2030年

小児がんバイオマーカー市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の小児がんバイオマーカー市場規模は2030年までに14億5,000万米ドルに達すると予測され、2024年から2030年にかけてCAGR 8.5％で成長すると予測されています。

世界の小児がん患者数の増加が市場拡大の主な要因です。2023年2月のNIH報告書によると、世界全体で毎年約40万人の0～19歳の小児および青年ががんと診断されています。小児がんは成人のがんとは異なり、白血病が最も多く、次いで中枢神経系（CNS）腫瘍とリンパ腫が多いです。様々な医療機関によると、小児がんは成人がんよりも稀ではあるが、診断技術の向上と意識の高まりにより、診断される機会が増えています。

小児がんの早期発見と治療を促進する新しいバイオマーカーを発見するための多大な調査努力が行われています。例えば、2024年6月、フィラデルフィア小児病院（CHOP）の研究者らは、新しい免疫ベースのバイオマーカーの発見を発表しました。この有望なバイオマーカーは、早期発見法に革命をもたらす可能性があり、卵巣がんが一般的に顕在化する2～4年前に発見できる可能性があります。このようなブレークスルーは、小児腫瘍学の治療成績と生存率を向上させるために極めて重要です。研究が革新的なバイオマーカーを生み出し続けるにつれ、市場は拡大し、高度な診断ツールの開発への投資と集中が高まっています。この進歩は、より早期で正確な診断をサポートするだけでなく、小児がんバイオマーカー市場全体の成長を牽引しています。

さらに、学術機関、研究機関、製薬会社の連携が小児がんバイオマーカー市場のイノベーションを促進しています。共同研究やパートナーシップは、専門知識やリソースを共有することで新たなバイオマーカーの開発や検証を促進します。例えば、ランタンファーマは2022年2月、テキサス大学ヘルスサイエンスセンターのThe Greehey Children Cancer Research Instituteとの提携を通じて、さらなる小児がんへの進出を発表しました。研究や官民パートナーシップは、先進的なバイオマーカーの発見と商業化を加速します。これらのパートナーシップは研究開発プロセスの効率を高め、新規バイオマーカーをより迅速かつ効果的に市場に投入することで市場の成長に貢献します。

さらに、特に新興市場におけるヘルスケアインフラの拡大と改善が、小児がんバイオマーカー市場の成長を促進しています。様々な地域のヘルスケアシステムが発展し近代化するにつれて、先進的な診断技術やバイオマーカー検査へのアクセスが向上しています。ヘルスケア施設とサービスの向上により、小児がんバイオマーカーの広範な導入が可能になり、診断精度と治療効果が向上します。

小児がんバイオマーカー市場レポート・ハイライト

• 適応症別では、白血病分野が2023年に40.8%の最大シェアを占めました。
• バイオマーカー別では、CD19、CD20、CD22の各セグメントが、血液がんの診断と標的化において重要な役割を果たすため、2023年に29.7%の最大シェアを占めました。CAR-T細胞療法などの標的治療の進歩は、治療効果と患者の転帰を改善するためにこれらのバイオマーカーを利用しています。精密医療への応用の拡大は、市場拡大に大きく寄与しています。
• 最終用途別では、病院分野が2023年に40.5%の最大シェアを占め、投資と政府支援の増加が牽引しています。病院は、小児がんの診断精度の向上と個別化治療のために高度なバイオマーカー技術を導入しています。研究開発への資金提供や革新的な診断法の導入に対する奨励金などの政府の取り組みが市場拡大を後押ししています。
• 北米の小児がんバイオマーカー市場は、先進的な研究、がん罹患率の増加、ヘルスケアインフラへの多額の投資により、世界市場全体を支配し、2023年には43.8%の売上シェアを占めました。診断技術の強化や個別化医療への注目が市場拡大の原動力となっているほか、小児がんの研究や治療に対する多額の資金提供や政府の支援政策も後押ししています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 小児がんバイオマーカー市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 小児がんバイオマーカー市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 小児がんバイオマーカー市場：適応症の推定・動向分析

• セグメントダッシュボード
• 小児がんバイオマーカー市場：適応症変動分析
• 小児がんバイオマーカー市場：適応症別展望
• 2018年から2030年までの市場規模と予測・動向分析
• 白血病
• 神経芽細胞腫
• 中枢神経系腫瘍
• リンパ腫
• その他

第5章 小児がんバイオマーカー市場：バイオマーカーの推定・動向分析

• セグメントダッシュボード
• 小児がんバイオマーカー市場：バイオマーカー変動分析
• 小児がんバイオマーカー市場：バイオマーカー別展望
• 2018年から2030年までの市場規模と予測・動向分析
• アルファフェトプロテイン（AFP）
• ニューロン特異的エノラーゼ（NSE）
• CD19、CD20、CD22
• ALK（未分化リンパ腫受容体チロシンキナーゼ遺伝子）
• その他

第6章 小児がんバイオマーカー市場：最終用途の推定・動向分析

• セグメントダッシュボード
• 小児がんバイオマーカー市場：最終用途変動分析
• 小児がんバイオマーカー市場：最終用途別展望
• 2018年から2030年までの市場規模と予測・動向分析
• 病院
• 診断検査室
• 腫瘍学センター
• 調査機関

第7章 小児がんバイオマーカー市場：地域の推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 市場参入企業の分類
• 主要市場参入企業による最近の動向と影響分析
• 戦略マッピング
• 主要企業プロファイル
  • F. Hoffmann-La Roche Ltd
  • Abbott
  • Siemens Healthineers
  • Thermo Fisher Scientific
  • QIAGEN
  • Myriad Genetics
  • Beckman Coulter
  • Bio-Rad Laboratories
  • Agilent Technologies
  • BIOMERIEUX
  • RayBiotech, Inc
  • Randox Laboratories Ltd.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 4 Global pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 5 Global pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 6 North America pediatric cancer biomarkers market, by region, 2018 - 2030 (USD Million)
• Table 7 North America pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 8 North America pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 9 North America pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 10 U.S. pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 11 U.S. pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 12 U.S. pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 13 Canada pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 14 Canada pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 15 Canada pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 16 Mexico pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 17 Mexico pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 18 Mexico pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 19 Europe pediatric cancer biomarkers market, by country, 2018 - 2030 (USD Million)
• Table 20 Europe pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 21 Europe pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 22 Europe pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 23 UK pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 24 UK pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 25 UK pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 26 Germany pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 27 Germany pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 28 Germany pediatric cancer biomarkers market, by end use 2018 - 2030 (USD Million)
• Table 29 France pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 30 France pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 31 France pediatric cancer biomarkers market, by end use 2018 - 2030 (USD Million)
• Table 32 Italy pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 33 Italy pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 34 Italy pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 35 Spain pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 36 Spain pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 37 Spain pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 38 Denmark pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 39 Denmark pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 40 Denmark pediatric cancer biomarkers market, by end use 2018 - 2030 (USD Million)
• Table 41 Norway pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 42 Norway pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 43 Norway pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 44 Sweden pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 45 Sweden pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 46 Sweden pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific pediatric cancer biomarkers market, by country, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 51 Japan pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 52 Japan pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 53 Japan pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 54 China pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 55 China pediatric cancer biomarkers market, by biomarker 2018 - 2030 (USD Million)
• Table 56 China pediatric cancer biomarkers market, by end use 2018 - 2030 (USD Million)
• Table 57 India pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 58 India pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 59 India pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 60 Australia pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 61 Australia pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 62 Australia pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 63 South Korea pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 64 South Korea pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 65 South Korea pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 66 Thailand pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 67 Thailand pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 68 Thailand pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 69 Latin America pediatric cancer biomarkers market, by country, 2018 - 2030 (USD Million)
• Table 70 Latin America pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 71 Latin America pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 72 Latin America pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 73 Brazil pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 74 Brazil pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 75 Brazil pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 76 Argentina pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 77 Argentina pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 78 Argentina pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 79 Middle East & Africa pediatric cancer biomarkers market, by country, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 83 South Africa pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 84 South Africa pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 85 South Africa pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 89 UAE pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 90 UAE pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 91 UAE pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
• Table 92 Kuwait pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
• Table 93 Kuwait pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
• Table 94 Kuwait pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Information procurement
• Fig. 2 Primary research pattern
• Fig. 3 Market research approaches
• Fig. 4 Value chain-based sizing & forecasting
• Fig. 5 Market formulation & validation
• Fig. 6 Pediatric cancer biomarkers market segmentation
• Fig. 7 Market driver analysis (current & future impact)
• Fig. 8 Market restraint analysis (current & future impact)
• Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 10 Porter's five forces analysis
• Fig. 11 Pediatric cancer biomarkers market, indication outlook key takeaways (USD Million)
• Fig. 12 Pediatric cancer biomarkers market: indication movement analysis 2023 & 2030 (USD Million)
• Fig. 13 Leukemia market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 14 Neuroblastoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 15 CNS tumors market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 16 Lymphoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 17 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 18 Pediatric cancer biomarkers market, biomarker outlook key takeaways (USD Million)
• Fig. 19 Pediatric cancer biomarkers market: biomarker movement analysis 2023 & 2030 (USD Million)
• Fig. 20 Pediatric market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Alpha-fetoprotein (AFP) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Neuron-specific enolase (NSE) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 CD19, CD20, CD22 market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 ALK (anaplastic lymphoma receptor tyrosine kinase gene) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Pediatric cancer biomarkers market, end use outlook key takeaways (USD Million)
• Fig. 27 Pediatric cancer biomarkers market: end use movement analysis 2023 & 2030 (USD Million)
• Fig. 28 Hospital market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Diagnostic laboratories market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Oncology centers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Research institutions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Pediatric cancer biomarkers market: regional key takeaways (USD Million)
• Fig. 33 Pediatric cancer biomarkers market: regional outlook, 2023 & 2030 (USD Million)
• Fig. 34 North America pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 US pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Canada pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Mexico pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Europe pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 UK pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Germany pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 France pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Spain pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Italy pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Norway pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Denmark pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Sweden pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Asia Pacific pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 China pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Japan pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 India pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 South Korea pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Australia pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Thailand pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Latin America pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Brazil pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Argentina pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Middle East and Africa pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 South Africa pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Saudi Arabia pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 UAE pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Kuwait pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 List of key emerging company's/biomarker disruptors/innovators

Pediatric Cancer Biomarkers Market Growth & Trends:

The global pediatric cancer biomarkers market size is anticipated to reach USD 1.45 billion by 2030 and is projected to grow at a CAGR 8.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rise in the number of pediatric cancer cases globally is a major driver for market expansion. According to a February 2023 NIH report, approximately 400,000 children and adolescents aged 0-19 are diagnosed with cancer globally each year. Pediatric cancers are distinct from those in adults, with the most prevalent types being leukemias, followed by central nervous system (CNS) tumors and lymphomas. According to various health organizations, pediatric cancers, while rarer than adult cancers, are increasingly being diagnosed due to better diagnostic technologies and heightened awareness.

Significant research efforts are uncovering novel biomarkers that can enhance early detection and treatment of pediatric cancers. For instance, in June 2024, researchers at the Children's Hospital of Philadelphia (CHOP) announced the discovery of a new immune-based biomarker. This promising biomarker could revolutionize early detection methods, potentially identifying ovarian cancer two to four years before it typically manifests. Such breakthroughs are crucial for improving pediatric oncology treatment outcomes and survival rates. As research continues to yield innovative biomarkers, the market is expanding, with increased investments and focus on developing advanced diagnostic tools. This progress not only supports earlier and more accurate diagnosis but also drives the overall growth of the pediatric cancer biomarkers market.

Additionally, collaboration between academic institutions, research organizations, and pharmaceutical companies drives innovation in the pediatric cancer biomarkers market. Joint research efforts and partnerships facilitate developing and validating new biomarkers through shared expertise and resources. Collaborative initiatives, such as multi-center For instance, in February 2022, Lantern Pharma announced its expansion into additional pediatric cancers through a partnership with The Greehey Children Cancer Research Institute at the University of Texas Health Science Center. studies and public-private partnerships, accelerate the discovery and commercialization of advanced biomarkers. These partnerships enhance the efficiency of research and development processes, contributing to market growth by bringing novel biomarkers to market more rapidly and effectively.

Furthermore, the expansion and improvement of healthcare infrastructure, particularly in emerging markets, are facilitating the growth of the pediatric cancer biomarkers market. As healthcare systems in various regions develop and modernize, there is greater access to advanced diagnostic technologies and biomarker tests. Improved healthcare facilities and services enable the broader implementation of pediatric cancer biomarkers, enhancing diagnostic accuracy and treatment efficacy.

Pediatric Cancer Biomarkers Market Report Highlights:

• Based on indication, the leukemia segment held the largest share of 40.8% in 2023, owing to the high incidence and need for early detection of this cancer type.
• Based on biomarker, the CD19, CD20, and CD22 segments held the largest share of 29.7% in 2023, due to their critical roles in diagnosing and targeting hematological cancers. Advances in targeted therapies, such as CAR-T cell therapies, utilize these biomarkers to improve treatment efficacy and patient outcomes. Their growing application in precision medicine is significantly contributing to market expansion.
• In terms of end use, the hospital segment held the largest share of 40.5% in 2023, driven by increasing investments and government support. Hospitals are adopting advanced biomarker technologies to improve diagnostic accuracy and personalized treatments for pediatric cancers. Government initiatives, such as funding for research and development and incentives for implementing innovative diagnostics, are bolstering market expansion.
• North America pediatric cancer biomarkers market dominated the overall global market and accounted for the 43.8% revenue share in 2023due to advanced research, increasing cancer incidence, and significant investments in healthcare infrastructure. Enhanced diagnostic technologies and a focus on personalized medicine are driving market expansion, alongside substantial funding and supportive government policies for pediatric cancer research and treatment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Biomarker
  • 1.2.3. End use
  • 1.2.4. Regional Scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Indication outlook
  • 2.2.2. Biomarker outlook
  • 2.2.3. End use outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Pediatric Cancer Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Incidence of Pediatric Cancer
    • 3.2.1.2. Growing Awareness and Government Initiatives
    • 3.2.1.3. Advancements in Genomics and Proteomics
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Costs of Research and Development
    • 3.2.2.2. Complex Regulatory Requirements
• 3.3. Pediatric Cancer Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Pediatric Cancer Biomarkers Market: Indication Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Pediatric Cancer Biomarkers Market: Indication Movement Analysis
• 4.3. Pediatric Cancer Biomarkers Market by Indication Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Leukemia
  • 4.5.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Neuroblastoma
  • 4.6.1. Neuroblastoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. CNS Tumors
  • 4.7.1. CNS Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Lymphoma
  • 4.8.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pediatric Cancer Biomarkers Market: Biomarker Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Pediatric Cancer Biomarkers Market: Biomarker Movement Analysis
• 5.3. Pediatric Cancer Biomarkers Market by Biomarker Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Alpha-fetoprotein (AFP)
  • 5.5.1. Alpha-fetoprotein (AFP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Neuron-specific enolase (NSE)
  • 5.6.1. Neuron-specific enolase (NSE) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. CD19, CD20, CD22
  • 5.7.1. CD19, CD20, CD22 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. ALK (anaplastic lymphoma receptor tyrosine kinase gene)
  • 5.8.1. ALK (anaplastic lymphoma receptor tyrosine kinase gene) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pediatric Cancer Biomarkers Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Pediatric Cancer Biomarkers Market: End Use Movement Analysis
• 6.3. Pediatric Cancer Biomarkers Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Hospital
  • 6.5.1. Hospital Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Diagnostic Laboratories
  • 6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Oncology Centers
  • 6.7.1. Oncology Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Research Institutions
  • 6.8.1. Research Institutions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pediatric Cancer Biomarkers Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Recent Developments & Impact Analysis by Key Market Participants
• 8.3. Strategy Mapping
• 8.4. Key Company Profiles
  • 8.4.1. F. Hoffmann-La Roche Ltd
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Abbott
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Siemens Healthineers
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Thermo Fisher Scientific
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. QIAGEN
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Myriad Genetics
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Beckman Coulter
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Bio-Rad Laboratories
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Agilent Technologies
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. BIOMERIEUX
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. RayBiotech, Inc
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. Randox Laboratories Ltd.
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Product benchmarking
    • 8.4.12.4. Strategic initiatives